Latest news with #UnmeshLal
Cision Canada
22-07-2025
- Business
- Cision Canada
BostonGene Receives Frost & Sullivan's 2025 North American Enabling Technology Leadership Award for Redefining Precision Oncology with AI and Multiomics Innovation
BostonGene's comprehensive AI-powered platform integrates multiomics data to accelerate discovery, reduce development risk and advance precision oncology across all stages the R&D continuum SAN ANTONIO , July 22, 2025 /CNW/ -- Frost & Sullivan has named BostonGene the recipient of the 2025 North American Enabling Technology Leadership Award in recognition of the company's pioneering role in advancing precision oncology. BostonGene's clinically validated, AI-powered platform uses a multimodal approach to decode disease and uncover predictive biological signatures. BostonGene combines data from genes, RNA, proteins, the immune system and the tumor environment to help pharma and biotech develop targeted therapies, design efficient trials, and improve outcomes. Its "Comprehensive Digital Patient" model enables precise drug targeting, biomarker validation and patient stratification. With high test success and fast turnaround, BostonGene accelerates data-driven clinical decisions. "BostonGene has developed state-of-the-art AI-driven, next-generation analytics technologies and is the only known source capable of delivering such comprehensive and integrated analyses," said Unmesh Lal , Healthcare Research Director at Frost & Sullivan. "What truly differentiates BostonGene is its ability to turn vast, complex datasets into clinically meaningful insights with speed and accuracy—delivering real impact not just in research settings but in real-world clinical and drug development environments where timely, actionable data is critical." Backed by a decade of scientific investment and a growing intellectual property portfolio, BostonGene's capabilities span internal lab services, advanced analytics and multimodal assay integration. Its CLIA-certified, CAP-accredited and NYS-approved regulatory infrastructure ensures quality and compliance across global partnerships. "By delivering tailored solutions, accelerating project timelines and driving innovation through advanced analytics, BostonGene is fundamentally transforming oncology drug development," said Manuel Albornoz , Best Practices Research Analyst at Frost & Sullivan. "Its adaptability, speed and scientific rigor make it a trusted partner for the industry." "This recognition reinforces our commitment to equipping drug developers with the tools they need to make smarter, faster decisions," said Nathan Fowler , MD, Chief Medical Officer at BostonGene. "By integrating multiomic data and modeling the tumor microenvironment, we help our partners optimize trial design, improve patient selection and accelerate the development of targeted therapies." Each year, Frost & Sullivan presents this award to a company that has developed a breakthrough technology with the potential to significantly enhance existing products and enable the creation of new solutions and applications. The award highlights technologies with strong potential for market adoption and industry impact. Frost & Sullivan Best Practices Awards honor companies across regional and global markets that demonstrate excellence in innovation, leadership, customer service and strategic product development. Recipients are selected through a rigorous evaluation process involving in-depth interviews, market analysis and extensive secondary research to identify companies that set the benchmark for industry best practices. Read the final report here. About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion . Contact: Ashley Shreve Marketing Coordinator - Best Practices Recognition [email protected] Phone: +1.210.844.2505 About BostonGene Corporation BostonGene helps drug developers de-risk and accelerate research and development using a clinically validated AI platform purpose-built for oncology and supported by a CLIA-certified and CAP-accredited clinical laboratory. By integrating advanced molecular and immune profiling with clinical data, we uncover actionable insights that inform trial design, optimize patient selection and improve clinical outcomes. Our diagnostic and treatment recommendation solutions are used in clinical settings to personalize care and guide therapy decisions for patients. For more information, visit .For more information, visit . Contact: Erin Keleher [email protected] Phone: +1-617-283-2285 SOURCE Frost & Sullivan
Business Wire
03-07-2025
- Business
- Business Wire
Frost & Sullivan Recognizes Novotech as 2025 Global Biotech CRO Company of the Year
SYDNEY--(BUSINESS WIRE)--In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost & Sullivan. In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost & Sullivan. Share Novotech is a globally recognized full-service clinical CRO and scientific advisory firm, trusted by biotech and small- to mid-sized pharmaceutical companies to advance their drug development programs at every phase. With a global footprint spanning Asia-Pacific, North America, and Europe, Novotech supports over 5,000 clinical trial sites and a distributed team of experts delivering seamless, end-to-end solutions across geographies. 'Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for small to mid-size biotech, Novotech leverages deep therapeutic expertise and regional agility to deliver speed, flexibility, and transformative impact in clinical trials.' — Unmesh Lal, Vice President – Healthcare & Life Sciences, Frost & Sullivan According to Frost & Sullivan, Novotech's client-first approach, coupled with its scale and scientific capabilities, continues to set it apart in the biotech CRO space. The firm's deep therapeutic expertise in oncology, rare diseases, infectious diseases, and advanced modalities—such as gene therapies and RNA-based treatments—was cited as a key differentiator. The award also acknowledged Novotech's ability to maintain trial continuity and delivery excellence amid geopolitical, operational, and economic volatility. Strategic use of AI-enabled tools, predictive analytics, and real-time data platforms further enables Novotech to accelerate timelines and improve decision-making for biotech sponsors. 'We're honored by Frost & Sullivan's recognition, which highlights Novotech's strategic focus on delivering regional expertise through a global model to support biotech and mid-size pharma sponsors. It also reflects the strength of our teams in driving operational, scientific, and client delivery excellence worldwide.' — Dr. John Moller, CEO, Novotech Unmesh Lal added: 'Frost & Sullivan believes Novotech's road ahead is about growing without losing its soul: scaling globally while staying deeply connected to biotech clients, preserving its cultural DNA, and delivering the high-touch, high-value service that has become its hallmark.' The award was accepted on behalf of Novotech by Scott Schliebner, Vice President of Drug Development Consulting, during the Frost & Sullivan Excellence in Best Practices Awards Gala held in Los Angeles, California, on June 26. About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results. For more information or to speak to an expert team member visit
Cision Canada
03-07-2025
- Business
- Cision Canada
Novotech Earns Frost & Sullivan's 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services
Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech sets the global standard in contract research for biotechs and small- mid-size pharma companies. SAN ANTONIO, July 3, 2025 /CNW/ -- Frost & Sullivan is pleased to announce that Novotech has been awarded the 2025 Global Company of the Year Award in the biotech contract research organization (CRO) industry for its outstanding achievements in clinical trial innovation, strategic execution, and client-centric delivery. This recognition highlights Novotech's leadership in enabling biotech and small to mid-sized pharma companies to accelerate therapeutic development globally through flexible, high-touch, and technologically advanced clinical trial services. The company stands apart in the global CRO landscape with its strategic emphasis on serving biotech clients, offering tailored clinical trial solutions across all phases of development. The company operates in more than 30 locations and has cultivated deep local insights across key clinical trial hubs, including Australia, South Korea, India, China, and the United States. Its ability to combine global standards with regional excellence makes Novotech a trusted partner for biotech sponsors worldwide. "Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for biotech and small to midsize pharma, Novotech leverages deep therapeutic expertise and regional agility to deliver speed, flexibility, and transformative impact in clinical trials," said Unmesh Lal, vice president, healthcare & life sciences at Frost & Sullivan. With nearly three decades of experience, Novotech has built a robust reputation for delivering high-quality clinical trials at speed. Its integrated service model encompasses regulatory consulting, clinical operations, biometrics, data management, and medical writing, allowing clients to streamline their development pipelines from early phase to post-marketing studies. Through a powerful combination of local knowledge, scientific expertise, and digital capabilities, Novotech continues to enhance trial efficiency, patient recruitment, and regulatory outcomes. Novotech's dedication to advancing clinical research is further reflected in its strategic acquisitions and partnerships. The company's expansions into the United States and Europe marked a significant milestone in building a globally unified platform while preserving its excellence in APAC operations. Novotech's sustained growth trajectory is driven by its deep alignment with sponsors' evolving needs and its commitment to scientific excellence and operational agility. "We're honored by Frost & Sullivan's recognition, which highlights Novotech's strategic focus on delivering regional expertise through a global model to support biotech and mid-size pharma sponsors. It also reflects the strength of our teams in driving operational, scientific, and client delivery excellence worldwide," said Dr. John Moller, chief executive officer, Novotech Novotech's unwavering commitment to client experience strengthens its position in the market. By streamlining service delivery, enabling real-time trial visibility through advanced digital systems, and maintaining continuity across project teams, the company delivers exceptional client satisfaction. Its regionalized, partner-led delivery model and localized expertise ensure regulatory compliance and cultural alignment—key factors that drive trial success in various markets. Frost & Sullivan commends Novotech for setting a high standard in competitive strategy, execution, and market responsiveness. The company's vision, innovation pipeline, and client-first culture are shaping the future of biotech clinical trials and driving tangible outcomes that matter to patients and sponsors. Each year, Frost & Sullivan presents the Company of the Year Award to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, client satisfaction, and competitive positioning. The award recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence. Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, client service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry. About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact: Tarini Singh E: [email protected] About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results.
Yahoo
14-05-2025
- Business
- Yahoo
Avance Clinical Honored with Frost & Sullivan's 2025 Global Customer Value Leadership Award for Transformative Biotech CRO Services
This award recognizes Avance Clinical's strategic innovation, operational agility, and unwavering commitment to client success in early-phase clinical trials. SAN ANTONIO, May 14, 2025 /PRNewswire/ -- Frost & Sullivan has named Avance Clinical the recipient of its 2025 Global Customer Value Leadership Award in the biotech contract research organization (CRO) sector, highlighting the company's outstanding performance in delivering exceptional client value through innovation, service excellence, and technology-enabled trial optimization. The accolade reinforces Avance Clinical's position as a trusted CRO partner that is uniquely equipped to support biotech sponsors navigating the complexities of early-phase research. Each year, Frost & Sullivan undertakes a comprehensive, independent analysis to benchmark companies on two core criteria—strategy alignment and execution effectiveness. Avance Clinical demonstrated clear leadership across both dimensions, offering a compelling combination of agility, scientific rigor, and digital innovation that continues to shape the biotech CRO landscape. According to Unmesh Lal, Vice President - Healthcare & Life Sciences at Frost & Sullivan, "Avance Clinical is positioning itself as a next-generation CRO with a deeply patient-centric and globally adaptive model. Under Yvonne Lungershausen's leadership, the company is striking a rare balance between innovation and regulatory rigor—leveraging technology to accelerate clinical trials while preserving scientific integrity. Their strategic focus on partnerships to drive global expansion, coupled with strong client retention and a commitment to quality, makes Avance a compelling player in the evolving biotech services landscape. Avance Clinical's growth strategy is built on its ability to anticipate and respond to market shifts, whether through digital transformation, data-driven decision-making, or strategic geographic expansion. The company's integration of artificial intelligence into core clinical operations—such as protocol development, medical writing, and workforce optimization—enables faster, more reliable outcomes for biotech innovators. By embedding intelligent automation into traditional manual workflows, Avance Clinical helps clients streamline study timelines while upholding the highest regulatory compliance and scientific integrity standards. These capabilities have positioned the company as a go-to CRO for sponsors seeking speed, quality, and flexibility in their clinical programs. Avance Clinical Chief Executive Officer, Yvonne Lungershausen said, "We are honored to receive this recognition from Frost & Sullivan, whose deep industry expertise and thoughtful analysis have been invaluable in highlighting what truly matters to our customers. At Avance Clinical, we are driven to be a smarter, faster, and more strategic partner for our clients because every patient deserves a future — that mission is at the heart of everything we do." Beyond its technical strengths, Avance Clinical distinguishes itself through a deeply customer-focused model. Through real-time milestone reviews, proactive risk mitigation, and transparent communication, the company fosters long-term client relationships built on trust, performance, and shared goals. Its structured project oversight, workforce training, and quality framework consistently drive high satisfaction and retention rates among biotech sponsors worldwide. Frost & Sullivan recognizes Avance Clinical's ability to translate strategic foresight into measurable impacts, supporting biotech sponsors as they navigate increasing regulatory scrutiny, financial pressures, and extended development timelines. The company's dedication to continuous improvement, global expansion, and collaborative innovation ensures its clients remain competitive in a fast-changing market. The Global Customer Value Leadership Award is one of Frost & Sullivan's highest honors, presented to organizations that elevate industry standards through breakthrough strategies and customer-centric delivery. Winners are selected based on demonstrated excellence in driving customer success, strengthening market standing, and translating strategic vision into scalable, high-impact outcomes. Frost & Sullivan's Best Practices Awards are the result of extensive independent research, comparing market participants on performance indicators such as growth strategy, innovation, customer engagement, and operational execution. The awards celebrate companies that have risen above the competition to deliver best-in-class results and set benchmarks for success across global industries. About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact: Tarini SinghE: About Avance Clinical Avance Clinical is a leading Contract Research Organization (CRO) offering biotech companies faster, more flexible, and higher-quality clinical trial services. As the largest premium full-service CRO headquartered in Australia, Avance Clinical delivers globally accepted data across Australia, New Zealand, Asia, North America, and Europe for international biotechs. With 30 years of experience and expertise spanning over more than 250 indications, the company provides comprehensive clinical research services from early to late-phase trials. Media Enquiries: media@ View original content to download multimedia: SOURCE Frost & Sullivan Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
14-05-2025
- Business
- Cision Canada
Avance Clinical Honored with Frost & Sullivan's 2025 Global Customer Value Leadership Award for Transformative Biotech CRO Services
This award recognizes Avance Clinical's strategic innovation, operational agility, and unwavering commitment to client success in early-phase clinical trials. SAN ANTONIO, May 14, 2025 /CNW/ -- Frost & Sullivan has named Avance Clinical the recipient of its 2025 Global Customer Value Leadership Award in the biotech contract research organization (CRO) sector, highlighting the company's outstanding performance in delivering exceptional client value through innovation, service excellence, and technology-enabled trial optimization. The accolade reinforces Avance Clinical's position as a trusted CRO partner that is uniquely equipped to support biotech sponsors navigating the complexities of early-phase research. Each year, Frost & Sullivan undertakes a comprehensive, independent analysis to benchmark companies on two core criteria—strategy alignment and execution effectiveness. Avance Clinical demonstrated clear leadership across both dimensions, offering a compelling combination of agility, scientific rigor, and digital innovation that continues to shape the biotech CRO landscape. According to Unmesh Lal, Vice President - Healthcare & Life Sciences at Frost & Sullivan, "Avance Clinical is positioning itself as a next-generation CRO with a deeply patient-centric and globally adaptive model. Under Yvonne Lungershausen's leadership, the company is striking a rare balance between innovation and regulatory rigor—leveraging technology to accelerate clinical trials while preserving scientific integrity. Their strategic focus on partnerships to drive global expansion, coupled with strong client retention and a commitment to quality, makes Avance a compelling player in the evolving biotech services landscape. Avance Clinical's growth strategy is built on its ability to anticipate and respond to market shifts, whether through digital transformation, data-driven decision-making, or strategic geographic expansion. The company's integration of artificial intelligence into core clinical operations—such as protocol development, medical writing, and workforce optimization—enables faster, more reliable outcomes for biotech innovators. By embedding intelligent automation into traditional manual workflows, Avance Clinical helps clients streamline study timelines while upholding the highest regulatory compliance and scientific integrity standards. These capabilities have positioned the company as a go-to CRO for sponsors seeking speed, quality, and flexibility in their clinical programs. Avance Clinical Chief Executive Officer, Yvonne Lungershausen said, "We are honored to receive this recognition from Frost & Sullivan, whose deep industry expertise and thoughtful analysis have been invaluable in highlighting what truly matters to our customers. At Avance Clinical, we are driven to be a smarter, faster, and more strategic partner for our clients because every patient deserves a future — that mission is at the heart of everything we do." Beyond its technical strengths, Avance Clinical distinguishes itself through a deeply customer-focused model. Through real-time milestone reviews, proactive risk mitigation, and transparent communication, the company fosters long-term client relationships built on trust, performance, and shared goals. Its structured project oversight, workforce training, and quality framework consistently drive high satisfaction and retention rates among biotech sponsors worldwide. Frost & Sullivan recognizes Avance Clinical's ability to translate strategic foresight into measurable impacts, supporting biotech sponsors as they navigate increasing regulatory scrutiny, financial pressures, and extended development timelines. The company's dedication to continuous improvement, global expansion, and collaborative innovation ensures its clients remain competitive in a fast-changing market. The Global Customer Value Leadership Award is one of Frost & Sullivan's highest honors, presented to organizations that elevate industry standards through breakthrough strategies and customer-centric delivery. Winners are selected based on demonstrated excellence in driving customer success, strengthening market standing, and translating strategic vision into scalable, high-impact outcomes. Frost & Sullivan's Best Practices Awards are the result of extensive independent research, comparing market participants on performance indicators such as growth strategy, innovation, customer engagement, and operational execution. The awards celebrate companies that have risen above the competition to deliver best-in-class results and set benchmarks for success across global industries. About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact: Tarini Singh E: About Avance Clinical Avance Clinical is a leading Contract Research Organization (CRO) offering biotech companies faster, more flexible, and higher-quality clinical trial services. As the largest premium full-service CRO headquartered in Australia, Avance Clinical delivers globally accepted data across Australia, New Zealand, Asia, North America, and Europe for international biotechs. With 30 years of experience and expertise spanning over more than 250 indications, the company provides comprehensive clinical research services from early to late-phase trials.
